Edition:
United States

Imv Inc (IMV.TO)

IMV.TO on Toronto Stock Exchange

6.73CAD
21 Sep 2018
Change (% chg)

$-0.10 (-1.46%)
Prev Close
$6.83
Open
$6.83
Day's High
$6.84
Day's Low
$6.63
Volume
21,150
Avg. Vol
37,739
52-wk High
$9.49
52-wk Low
$3.33

Latest Key Developments (Source: Significant Developments)

IMV Announces Early Positive Results From Phase 2 Clinical Trial Of Lead Candidate DPX-Survivac In Combination With Merck’S Keytruda In Patients With DLBCL
Tuesday, 18 Sep 2018 07:05am EDT 

Sept 18 (Reuters) - Imv Inc ::IMV INC. ANNOUNCES EARLY POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL OF LEAD CANDIDATE DPX-SURVIVAC IN COMBINATION WITH MERCK’S KEYTRUDA® IN PATIENTS WITH DLBCL.IMV INC - DATA SHOWED TWO OF FIRST FOUR EVALUABLE PARTICIPANTS SHOWED TUMOR REGRESSIONS AT FIRST ON-TREATMENT CT SCAN.IMV INC - IN TRIAL, COMBINATION THERAPY APPEARS TO DEMONSTRATE AN ACCEPTABLE SAFETY PROFILE, WITH NO SERIOUS ADVERSE EVENTS REPORTED TO DATE.IMV INC - FIRST ENROLLED PARTICIPANT DEMONSTRATED A TUMOR REGRESSION OF 48% AT FIRST ON-TREATMENT SCAN.IMV INC - SECOND PARTICIPANT DEMONSTRATED A PARTIAL RESPONSE (PR) VIA A TUMOR REGRESSION OF 66% AT FIRST ON-TREATMENT SCAN.IMV INC - PRELIMINARY DATA FROM THIRD PARTICIPANT IN TRIAL OF DPX-SURVIVAC IN COMBINATION WITH KEYTRUDA DEMONSTRATED STABLE DISEASE.IMV INC - FOURTH PARTICIPANT HAD EARLY DISEASE PROGRESSION LESS THAN TWO MONTHS FOLLOWING TREATMENT INITIATION AND WAS DISCONTINUED FROM STUDY.  Full Article

IMV Inc Files For Mixed Shelf Of Upto $150 Mln
Thursday, 31 May 2018 06:05pm EDT 

May 31 (Reuters) - Imv Inc ::IMV INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Immunovaccine Announces $12.5 Million Bought Deal Offering
Thursday, 25 Jan 2018 08:26am EST 

Jan 25 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES $12.5 MILLION BOUGHT DEAL OFFERING.IMMUNOVACCINE INC - ENTERED INTO BOUGHT DEAL FINANCING AGREEMENT TO SELL 6.3 MILLION COMMON SHARES AT A PRICE OF $2.00 PER COMMON SHARE.  Full Article

Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer
Tuesday, 5 Dec 2017 07:05am EST 

Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL​ SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVAC​DEMONSTRATE TOLERABLE SAFETY PROFILE.  Full Article

Immunovaccine reports qtrly loss per share of ‍$0.02​
Thursday, 9 Nov 2017 05:05pm EST 

Nov 9 (Reuters) - Immunovaccine Inc :Immunovaccine announces third quarter 2017 financial results.Immunovaccine Inc qtrly loss per share ‍$0.02​.  Full Article

Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac
Wednesday, 8 Nov 2017 07:05am EST 

Nov 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL.  Full Article

Immunovaccine Q2 loss per share C$0.02
Tuesday, 8 Aug 2017 05:05pm EDT 

Aug 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces financial results for quarter ended June 30, 2017.Q2 basic loss per share c$0.02.  Full Article

Immunovaccine announces achievement in personalized cancer medicines
Wednesday, 12 Jul 2017 07:05am EDT 

July 12 (Reuters) - Immunovaccine Inc :Immunovaccine achieves breakthrough in support of developing personalized cancer immunotherapies.Immunovaccine Inc - ‍filed a patent application covering the novel DepoVax-based rapid formulation process​.  Full Article

Immunovaccine announces $10 million bought deal offering
Wednesday, 31 May 2017 08:46am EDT 

May 31 (Reuters) - Immunovaccine Inc ::Immunovaccine announces $10 million bought deal offering.Immunovaccine Inc says intends to use net proceeds of offering to advance company's various depovax™-based products clinical studies.Immunovaccine Inc - entered into a bought deal financing agreement to sell 7.7 million common shares of corporation at a price of $1.30 per common share.Immunovaccine Inc - offering is expected to close on or about June 21, 2017.  Full Article

Immunovaccine says to initiate mid-stage trial of its blood cancer drug
Tuesday, 16 May 2017 07:05am EDT 

May 16 (Reuters) - Immunovaccine Inc :Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored phase 2 clinical trial in DLBCL in combination with approved anti-PD-1 drug.Immunovaccine Inc says expects trial to begin enrolling patients following receipt of regulatory clearance from Health Canada.  Full Article